# To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

> **NCT02063230** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Selumetinib 50mg
- **DRUG:** Selumetinib 25mg

## Key facts

- **NCT ID:** NCT02063230
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063230, "To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02063230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*